Batko Bogdan, Krawiec Piotr, Osieleniec Jolanta, Sułowicz Władysław
Małopolskie Centrum Reumatologii, Immunologii i Rehabilitacji, Oddział Reumatologii Szpitala Specjalistycznego im. J. Dietla w Krakowie.
Katedra i Klinika Nefrologii Uniwersytet Jagielloński, Collegium Medicum w Krakowie.
Przegl Lek. 2013;70(9):724-9.
Mycophenolate mofetil (MMF) is an inhibitor of inosine monophosphate dehydrogenase, which affects de novo purine synthesis and T- and B-cell proliferation. So far its efficacy and safety as an immunosuppressive treatment have been proven in organ transplantations and also in various autoimmune diseases. A literature search was conducted by using PubMed and the Cochrane library. This review focuses primarily on current treatment with MMF for systemic lupus erythematosus, systemic sclerosis, vasculitis and idiopathic inflammatory myopathies.
霉酚酸酯（MMF）是肌苷单磷酸脱氢酶的抑制剂，它影响嘌呤从头合成以及T细胞和B细胞增殖。到目前为止，其作为免疫抑制治疗的有效性和安全性已在器官移植以及各种自身免疫性疾病中得到证实。通过使用PubMed和Cochrane图书馆进行了文献检索。本综述主要关注目前用霉酚酸酯治疗系统性红斑狼疮、系统性硬化症、血管炎和特发性炎性肌病的情况。
